Moreover, it has beat estimates in each of the trailing four quarters, the average positive surprise being 10.7%.Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).The same for earnings stands at $8.15 per share, suggesting a fall of 36.1% from the year-ago reported figure.Stocks to ConsiderSome better-ranked stocks from the broader medical space include Quest Diagnostics Incorporated DGX, Laboratory Corporation of America Holdings LH and West Pharmaceutical Services, Inc. WST.